This competitive renewal application requests 5 additional years support for 5 post-doctoral trainees in cerebrovascular disease (stroke) to complete a 2 year fellowship. The program's mission is to develop neurologists to become clinician-scientists in cerebrovascular disease. Stroke is the number one cause of adult disability;effective treatments are urgently needed.
The specific aims of the training program are to: (1) provide opportunities for the study of clinical research in stroke;(2) provide trainin in laboratory investigation of cerebrovascular disease. The last 5 years of funding under the T32 Training Grant has resulted in significant growth in our stroke program on many fronts. Continued funding for another 5 years would therefore allow us to: 1) provide uninterrupted growth of our research mentoring program for stroke fellows;2) train ethnically diverse researchers and physician-scientists who will make an impact on treating cerebrovascular disease. Our overall goal is to help accomplish improved care of stroke patients by mentoring clinician-scientists who will dedicate their careers to investigating the pathophysiology and epidemiology of cerebrovascular disease and the application of this knowledge to new therapeutic advances. Faculty mentors have been carefully selected to provide a multidisciplinary training experience in cerebrovascular disease. Potential trainees must have completed a neurology residency and demonstrate a commitment to a career carrying out research in cerebrovascular disease.
The goal of our training program is to improve the care of stroke patients by mentoring and developing clinician-scientists in the field of cerebrovascular disease. We seek continued funding for our training program which enables our trainees to conduct high quality laboratory and clinical research in stroke and provides them critical support to launch their careers in academic medicine.
|Wu, Tzu-Ching; Sitton, Clark; Potter, Andrew et al. (2014) CTP infarct core may predict poor outcome in stroke patients treated with IV t-PA. J Neurol Sci 340:165-9|
|Alderazi, Yazan J; Barot, Niravkumar V; Peng, Hui et al. (2014) Clotting factors to treat thrombolysis-related symptomatic intracranial hemorrhage in acute ischemic stroke. J Stroke Cerebrovasc Dis 23:e207-14|
|Acosta, Indrani; Bloch, Sivan; Morales, Miriam et al. (2014) Predicting the need for hospital admission of TIA patients. J Neurol Sci 336:83-6|
|Wu, Tzu-Ching; Nguyen, Claude; Ankrom, Christy et al. (2014) Prehospital utility of rapid stroke evaluation using in-ambulance telemedicine: a pilot feasibility study. Stroke 45:2342-7|
|Bowry, Ritvij; Fraser, Stuart; Archeval-Lao, Joancy M et al. (2014) Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke 45:880-3|
|Savitz, Sean I (2013) Cell therapies: careful translation from animals to patients. Stroke 44:S107-9|
|Mir, Osman; Savitz, Sean I (2013) Stem cell therapy in stroke treatment: is it a viable option? Expert Rev Neurother 13:119-21|
|Sarraj, Amrou; Albright, Karen; Barreto, Andrew D et al. (2013) Optimizing prediction scores for poor outcome after intra-arterial therapy in anterior circulation acute ischemic stroke. Stroke 44:3324-30|
|Barreto, Andrew D; Alexandrov, Andrei V; Lyden, Pat et al. (2012) The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke 43:770-5|
|Wu, Tzu-Ching; Kasam, Mallik; Harun, Nusrat et al. (2011) Pharmacological deep vein thrombosis prophylaxis does not lead to hematoma expansion in intracerebral hemorrhage with intraventricular extension. Stroke 42:705-9|
Showing the most recent 10 out of 61 publications